KORU Medical Systems Inc

KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

KORU Medical Systems reports robust Q4 growth and eyes international expansion

KORU Medical Systems demonstrated strong financial performance in Q4 2022, with revenue growth and cash position exceeding expectations.
The company's strategic focus on novel therapies and international expansion presents growth opportunities, though margin improvement and market challenges remain.
With a clear Vision 26 strategy and positive revenue guidance for 2023, KORU is poised for continued growth and market leadership.

KORU Medical Systems excels in Q1 2023, poised for strategic growth

KORU Medical Systems delivered a robust performance in Q1 2023, showcasing growth across key business segments and strategic initiatives.
The company's focus on revenue targets, margin improvement, and operational efficiency positions it well for future success.
While challenges like managing cash burn and market dynamics exist, KORU's strengths in product leadership and financial management offer resilience.
Strategic opportunities in market expansion, innovation, and customer value creation provide a positive outlook for the company's growth trajectory.

KORU Medical Systems reports Q2 growth, projects improved margins

KORU Medical Systems demonstrated overall growth in Q2 2023, driven by strong performance in core businesses and improving gross margins. While facing challenges in Novel Therapies and a net cash operating loss, the company remains optimistic about future revenue growth and strategic initiatives.

KORU Medical Systems Inc reports Q3 revenue decline, focuses on margin expansion and Novel Therapies collaborations

KORU Medical Systems Inc faces revenue challenges but focuses on margin expansion, expense control, and strategic investments. The company aims for cash flow breakeven by Q4 2024, emphasizing Novel Therapies business and market growth assumptions.

KORU Medical Systems reports solid Q4 growth and outlines expansion plans for 2024

KORU Medical Systems' Q4 2023 performance reflects steady growth and strategic advancements in product development and market expansion. While facing challenges in production efficiency and European certification, the company is well-positioned to capitalize on opportunities in prefilled syringes and novel therapies for future growth.

KORU Medical Systems achieves record revenue and eyes global expansion

KORU Medical Systems delivered strong Q1 2024 results with record revenue and gross margin, alongside reduced cash burn.
The company reaffirmed guidance, secured new collaborations, and expanded internationally, while facing regulatory approval challenges.
Opportunities lie in FDA approvals, cash flow targets, and sustained U.S. core business growth through innovations and partnerships.

KORU Medical Systems excels in Q3, eyes growth opportunities

KORU Medical Systems delivered robust financial performance in Q3 2024, with raised revenue guidance and expectations of cash flow positivity in 2025.
The company's strategic focus on new product development and market expansion positions it well for sustained growth and profitability.
While facing challenges in maintaining growth momentum and operational efficiency, KORU's strong performance and outlook signal a promising future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)---- $KRMD #FRAUD--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Repro Med Systems, Inc. d/b/a KORU Medical Systems (“KORU” or the “Company”) (NASDAQ: KRMD) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your KORU investments or would like to inquire about potentially pursuing claims to recover your loss under

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Repro Med Systems, Inc. d/b/a KORU Medical Systems (KRMD) on Behalf of Investors

Repro Med Systems, Inc. (KRMD) Interim CEO Jim Beck on Q4 2020 Results - Earnings Call Transcript

Shares of Repro-Med Systems (NASDAQ:KRMD) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 0.00% year over year to ($0.02), which missed the estimate of ($0.01).

Repro-Med Systems: Q4 Earnings Insights

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company") a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the fourth quarter and full year ended December 31, 2020. 2020 Full Year Financial Highlights: Net revenue of $24.2 million Gros

KORU Medical Systems Reports Fourth Quarter and Full Year 2020 Financial Results

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that help improve quality of life for patients, today announced that Linda Tharby has been appointed President and Chief Executive Officer and will succeed Interim CEO Jim Beck effective April 12, 2021. Mr.

KORU Medical Systems Announces New Chief Executive Officer

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced that the Company will report fourth quarter and full year 2020 financial results on March 23, 2021. KORU Medical's management will host a conference

KORU Medical Systems to Report Fourth Quarter and Full Year 2020 Financial Results on March 23, 2021

Repro Med Systems (KRMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Repro Med Systems (KRMD) in Focus: Stock Moves 6.8% Higher

LOS ANGELES--(BUSINESS WIRE)---- $KRMD #investors--The Law Offices of Frank R. Cruz Announces Investigation of Repro Med Systems, Inc. dba KORU Medical Systems (KRMD) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Repro Med Systems, Inc. dba KORU Medical Systems (KRMD) on Behalf of Investors

The unexpected departure of the company's CEO appears to have rattled investors.

Why Repro Med Stock Is Sinking Today

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported preliminary financial results for the full year ended December 31, 2020. The Company also announced that seasoned home infusion executive and KORU Med

KORU Medical Systems Reports Preliminary Full Year 2020 Results; Announces CEO Transition

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that Don Pettigrew, President and Chief Executive Officer, will provide a company overview at the H.C. Wainwright BioConnect 2021 Conference, held virtually from January 11-14, 2021. A copy of the presentation will be available on the “Investors” section of the Company's website www.korumedical.com. About KORU Medical Systems KORU Medical Systems deve

KORU Medical Systems to Present at H.C. Wainwright BioConnect 2021 Conference

Repro Med Systems (KRMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Repro Med Systems (KRMD) Surges: Stock Moves 8.8% Higher

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that its Board of Directors has authorized a stock repurchase program under which the Company may purchase up to $10 million of its outstanding common stock through December 31, 2021. “We believe that this repurchase program demonstrates confidence in our long-term outlook, the underlying value of KORU Medical stock, and our commitment to maximizing v

KORU Medical Systems Announces Stock Repurchase Program

Repro Med Systems, Inc.'s (KRMD) CEO Donald Pettigrew on Q3 2020 Results - Earnings Call Transcript

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced financial results for the third quarter ended September 30, 2020 (“Q3 2020”). Q3 2020 Overview “The strength and resiliency of our core business, which provides our Freedom Integrated Infusion System to individuals with Primary Immune Deficiency Disease and Chronic Inflammatory Demyelinating Polyneuropathy, is helping us navigate the challenges of the

KORU Medical Systems Announces Financial Results for Third Quarter 2020

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that it will release its financial results for the third quarter ended September 30, 2020 after the close of the financial markets on Tuesday, November 3, 2020. Management will host a conference call on Wednesday, November 4, 2020 at 9:00 am ET to discuss the results and business activities. Interested parties may participate in the call by dialing: (

KORU Medical Systems Schedules Release of Third Quarter 2020 Financial Results and Conference Call

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc.

KORU Medical Systems to Present at Canaccord Genuity 40th Annual Growth Conference

Repro Med Systems, Inc.'s (KRMD) CEO Don Pettigrew on Q2 2020 Results - Earnings Call Transcript

KORU Medical Systems Announces 2020 Second Quarter Financial Results

KORU Medical Systems Schedules Release of Second Quarter 2020 Financial Results and Conference Call

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. d/b/a KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical”) today announced the appointment of Josh Bennett to the newly created position of Vice President Global Commercialization. Mr. Bennett brings 20 years of healthcare management and consulting experience to KORU Medical. He will be responsible for creating and executing initiatives designed to accelerate KORU Medical’s growth, with a focus on business development and product commercia

KORU Medical Systems Appoints Josh Bennett VP Global Commercialization

KORU Is Getting Tailwind From A Shift Away From IV And The Pandemic

Repro Med Systems, Inc. (KRMD) CEO Don Pettigrew on Q1 2020 Results - Earnings Call Transcript

KORU Medical Systems (KRMD) CEO Don Pettigrew on Q4 2019 Results - Earnings Call Transcript

KORU Medical Systems Growth Is Set To Continue

News for KORU Medical Systems Inc Stock (KRMD)